| 货号 | 规格 | 价格 | 上海 | 北京 | 珠海 | 重庆 | 武汉 | 购买数量 |
|---|---|---|---|---|---|---|---|---|
S82962-1mg买3赠1 |
99.80% | ￥125.00 |
5 | - | - | - | - |
|
S82962-5mg买3赠1 |
99.80% | ￥230.00 |
6 | - | - | - | - |
|
S82962-10mg买3赠1 |
99.80% | ￥420.00 |
6 | - | - | - | - |
|
S82962-50mg买3赠1 |
99.80% | ￥1650.00 |
3 | - | - | - | - |
|
S82962-100mg买3赠1 |
≥99% | ￥3200.00 |
货期：2-3天 | - | - | - | - |
|
| 产品描述： | Leniolisib (CDZ173) is a potent and selective PI3Kδ inhibitor. Leniolisib has the potential for immunodeficiency disorders treatment. | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶点： | PI3Kδ:11 nM (IC50);PI3Kα:280 nM (IC50);PI3Kβ:480 nM (IC50);PI3Kγ:2.57 μM (IC50);DNA-PK:880 nM (IC50);DNA-PK; PI3K | ||||||||||||||||||||
| 体外研究： | Expression of APDS mutant p110δ in cell lines and patient-derived lymphocytes lead to increased pathway activity, measured as phosphorylation of AKT or S6, which is suppressed by leniolisib in a concentration dependent way | ||||||||||||||||||||
| 体内研究： | Oral leniolisib lead to a dose-dependent reduction in PI3K/AKT pathway activity and resolve the immune dysregulation with normalization of circulating transitional and naïve B cells and reduction in PD-1+CD4+ and senescent CD57+CD8+ T cells. After 12 weeks of treatment, all patients show amelioration of lymphoproliferation with lymph node sizes and spleen volumes reduced by 39% (mean, range 26-57%) and 40% (mean, range: 13-65%), respectively | ||||||||||||||||||||
| 参考文献： | 1. Rao V, et al. Effective 'Activated PI3Kd Syndrome' -targeted therapy with PI3Kd inhibitor leniolisib. The New England journal of medicine: NEJM. ISSN 0028-4793; 1533-4406 | ||||||||||||||||||||
| 溶解性： | Soluble in DMSO | ||||||||||||||||||||
| 保存条件： | -20℃ | ||||||||||||||||||||
| 配置溶液浓度参考： |
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
